VasDeBlock
- User: Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Vas Deferens
-
Intended Duration:
- Long-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): VasDeBlock medical ApS
Details
-
Mechanism of Action:
- Vas Deferens Occlusion
- Inactive Materials: Polymer Gel Rods
- Regimen: One Application
- MPT: Not Potential MPT
- Promising Attributes: VasDeBlock is intended to offer users a reversible, non-surgical alternative to vasectomy.
Product Status
Active Pre-Clinical Research
History
2015: VasDeBlock ApS forms to develop a non-hormonal, non-surgical, reversible male contraceptive option
2019: Company receives first patent for their vas occlusion device. The company now holds patents in Europe, Japan, Australia, the US, and Canada (as of Jul. 2024)
VasDeBlock has announced that their device was successfully tested in pigs, and that pre-clinical testing is ongoing.